- Home
- LTC vs VRDN Comparison
LTC vs VRDN Comparison
Compare LTC & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LTC | VRDN |
|---|---|---|
| Founded | 1992 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.1B |
| IPO Year | 1994 | 2014 |
Fundamental Metrics
Financial Performance| Metric | LTC | VRDN |
|---|---|---|
| Price | $43.43 | $30.72 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 17 |
| Target Price | ★ $48.00 | $42.19 |
| AVG Volume (30 Days) | 637.4K | ★ 2.8M |
| Earning Date | 11-03-2026 | 11-04-2026 |
| Dividend Yield | ★ 5.21% | N/A |
| EPS Growth | ★ 23.53 | N/A |
| EPS | ★ 7.70 | N/A |
| Revenue | ★ $262,854,000.00 | $5,706,000.00 |
| Revenue This Year | $77.63 | $6.01 |
| Revenue Next Year | $56.98 | $316.34 |
| P/E Ratio | $5.71 | ★ N/A |
| Revenue Growth | ★ 25.26 | N/A |
| 52 Week Low | $33.64 | $13.18 |
| 52 Week High | $46.92 | $34.29 |
Technical Indicators
Market Signals| Indicator | LTC | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 46.73 | 78.19 |
| Support Level | $37.79 | $17.84 |
| Resistance Level | $43.61 | $30.79 |
| Average True Range (ATR) | 1.16 | 1.51 |
| MACD | -0.19 | 0.51 |
| Stochastic Oscillator | 32.85 | 89.10 |
Price Performance
Historical ComparisonAbout LTC LTC Properties Inc.
LTC Properties Inc is a real estate investment trust. It invests in seniors housing and health care properties, mainly through ownership, sale-leasebacks, mortgage financing, joint ventures, construction financing, and structured finance solutions, including preferred equity, bridge, and mezzanine lending. The company's investment portfolio comprises several properties located throughout the USA, the majority of which are seniors housing and skilled nursing properties. The firm conducts and manages its business as two operating segments: Real Estate Investments, which generates maximum revenue, and SHOP.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.